Kolon Life Science

코오롱생명과학 · 102940

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$480M (₩662.4B)

Overview

Kolon Life Science makes pharmaceutical ingredients and finished medicines, and also operates a supply-chain services business that handles logistics and distribution for other pharmaceutical companies.

Its products and services reach licensed drug manufacturers and healthcare providers. Listed on KOSDAQ, Korea's tech and small-cap exchange, the company runs three distinct divisions, pharmaceuticals, supply-chain services, and a biotechnology unit, with supply-chain services now accounting for the largest share of overall revenue.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$151.4M

▲ +29.5% YoY

Operating profit · FY2025

US$12.7M

Turned profitable

Net income · FY2025

US$18.1M

Turned profitable

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$90.3M(₩124.6B)	US$116.9M(₩161.4B)	US$151.4M(₩209B)
Operating profit	−US$17.5M(−₩24.1B)	−US$16M(−₩22.1B)	US$12.7M(₩17.6B)
Net income	−US$22.3M(−₩30.7B)	−US$67.5M(−₩93.1B)	US$18.1M(₩25B)

Revenue

FY2023US$90.3M
FY2024US$116.9M
FY2025US$151.4M

Operating profit

FY2023−US$17.5M
FY2024−US$16M
FY2025US$12.7M

Net income

FY2023−US$22.3M
FY2024−US$67.5M
FY2025US$18.1M

Key ratios (FY2025)

ROE

4.3%

Debt/Eq

56.6%

Op. margin

8.4%

Net margin

11.9%

Rev. YoY

▲ +29.5%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?